Valiant Organics Ltd

- The company is planning to do a CAPEX of around ₹80 to ₹90 crores this year. - To support this CAPEX, they are looking to retain cash flows and are also considering taking a term loan (debt). - There is no mention of any immediate or planned equity fundraising. - Buyback is not planned in the immediate future due to cash flow needs for CAPEX but might be considered going forward. - No specific details on any fresh equity issuance or large-scale debt raising were disclosed.

- Current year CAPEX is around ₹80-90 crores, including maintenance CAPEX of ₹20-30 crores. - Major CAPEX includes: - Process improvements and quality stabilization at existing plants (e.g., Ahmedabad, Sarigam, Tarapur). - Debottlenecking and infrastructure upgrades (e.g., ETPs, warehousing). - New systems installation like DCS at Tarapur and R&D center at Vapi. - No major large-scale expansions planned as recent expansions over last 3-4 years were significant. - Focus currently on stabilizing three ongoing projects rather than adding new capacity. - PAP project CAPEX approximately ₹270 crores, with payback period previously estimated at 3 years but currently uncertain due to price volatility. - No immediate plans for buybacks as cash is prioritized for CAPEX and possible term loans are being considered. - Management prefers to retain cash for ongoing and prioritized CAPEX rather than buybacks in the current market environment.

- FY24 H1 revenue declined 23.6% YoY to Rs. 405 crores due to weak demand and price corrections. - Volumes increased modestly (~7%) but prices fell ~5%, impacting revenue. - Chlorination chemistry currently at ~50% utilization; utilization expected to improve if European demand recovers in FY25. - PAP (Para Amino Phenol) capacity stabilizing; aiming for 600-800 tonnes/month, with ongoing CAPEX (~Rs. 20-30 crores) to achieve scale. - OAP (Ortho Amino Phenol) expected revenue around Rs. 30 crores at 100 tonnes/month production, though prices remain volatile. - Overall FY25 expected to be more prosperous with market demand revival, especially from Europe. - Current low utilization (~50%) at plants; focus on stabilizing existing capacities, not large CAPEX expansion due to underutilization risks. - Management cautious on margin and revenue guidance due to uncertain market conditions and volatile prices.

- The company expects a more prosperous FY25 with volume growth and stabilization in key products like PAP and OAP. - Current capacity utilization is around 50%, with plans to increase utilization to 80-90% contingent on market stabilization, especially in Europe. - Margins have compressed due to price corrections and lower demand but are expected to improve as volumes pick up and capacity utilization rises. - Expansion CAPEX is limited; focus is on stabilizing existing projects and improving process efficiencies, not major capacity increase given current underutilization. - Demand recovery in Europe and reduction in system inventories are key to driving higher utilization and earnings growth. - PAP production has crossed 500 tonnes per month, targeting 700-800 tonnes by year-end, which will support revenue and margin growth. - Margins and payback periods are uncertain currently due to price volatility but expected to normalize as capacity utilization and prices stabilize.

The transcript provided does not explicitly mention the current or expected order book or pending orders for Valiant Organics Limited. However, some relevant insights related to production and capacity utilization include: - OAP production is approximately 100 tonnes per month with revenue around Rs. 30 crores (prices may have changed recently). - Current plant capacity utilization is around 50% overall, with plans to stabilize recent expansions before further CAPEX. - Chlorination chemistry utilization is around 50-55%, with hopes to increase to 80-90% when demand, especially from Europe, improves. - PAP is running at around 80% utilization, but margins are volatile due to price fluctuations. - There is ongoing volume growth noted, with quarterly sales revenue around Rs. 200 crores. - No specific mention of confirmed pending orders or an official order book size was given during the call.